Linked Life Data

12875107

Source:http://linkedlifedata.com/resource/pubmed/id/12875107

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2003-7-23
pubmed:abstractText
Exposure to saquinavir can be increased considerably by pharmacokinetic enhancement with ritonavir, without having a substantial impact on tolerability. Clinical trials indicate that both once-daily and twice-daily saquinavir/ritonavir treatment regimens, generally at dosages of 1,600 mg/100 mg once daily and 1,000 mg/100 mg twice daily, provide potent and sustained viral suppression and are well tolerated. In addition, data suggest that "double-boosting" strategies, including the combination of saquinavir with lopinavir/ritonavir, provide valuable treatment options in the salvage setting.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1139-6121
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
44-51
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:articleTitle
Saquinavir/low-dose ritonavir: its use in HIV infection.
pubmed:affiliation
Infection and Immunity Services, Royal Free Hospital, Pons Street, London NW3 2QG, UK. ma@johnson.u-net.com
pubmed:publicationType
Journal Article, Review